Rocket Pharmaceuticals (RCKT) Cash & Equivalents (2014 - 2026)

Rocket Pharmaceuticals has disclosed Cash & Equivalents across 13 years of filings, most recently posting $144.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $144.4 million, up 189.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $144.4 million (up 189.9% YoY), and the FY2025 annual result was $77.6 million, down 52.6% from the prior year.
• Cash & Equivalents came in at $144.4 million for Q1 2026 at Rocket Pharmaceuticals, up from $77.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $360.0 million in Q1 2023 to a low of $35.3 million in Q1 2024.
• The 5-year median for Cash & Equivalents is $144.4 million (2026), against an average of $167.8 million.
• Across the five-year window, Cash & Equivalents plunged 90.2% in 2024 and surged 603.24% in 2025, its largest moves.
• Rocket Pharmaceuticals' Cash & Equivalents stood at $140.5 million in 2022, then sank by 60.22% to $55.9 million in 2023, then soared by 192.71% to $163.6 million in 2024, then slumped by 52.6% to $77.6 million in 2025, then soared by 86.18% to $144.4 million in 2026.
• The last three Cash & Equivalents figures came in at $144.4 million (Q1 2026), $77.6 million (Q4 2025), and $75.9 million (Q3 2025), per Business Quant data.